[NVM] Neuroventi Applies for Phase 2 Clinical IND for 'NV01-A02' Treat…
페이지 정보
조회 1,283회
작성일 24-03-26
본문
On February 23, Neuroventi submitted an application (IND) to the Ministry of Food and Drug Safety for approval of the Phase 2 clinical trial plan for NV01-A02, which is being developed as a treatment for autism spectrum disorder.
NV01-A02 is a substance discovered as an autism treatment through transcriptional analysis and pharmacological mechanisms of ASD patients and animal models using a drug re-creation strategy.